Abstract

Bladder cancer is a common malignant tumor of the urinary system. Despite recent advances in treatments such as local or systemic immunotherapy, chemotherapy, and radiotherapy, the high metastasis and recurrence rates, especially in muscle-invasive bladder cancer (MIBC), have led to the evaluation of more targeted and personalized approaches. A fundamental understanding of the tumorigenesis of bladder cancer along with the development of therapeutics to target processes and pathways implicated in bladder cancer has provided new avenues for the management of this disease. Accumulating evidence supports that the tumor microenvironment (TME) can be shaped by and reciprocally act on tumor cells, which reprograms and regulates tumor development, metastasis, and therapeutic responses. A hostile TME, caused by intrinsic tumor attributes (e.g., hypoxia, oxidative stress, and nutrient deprivation) or external stressors (e.g., chemotherapy and radiation), disrupts the normal synthesis and folding process of proteins in the endoplasmic reticulum (ER), culminating in a harmful situation called ER stress (ERS). ERS is a series of adaptive changes mediated by unfolded protein response (UPR), which is interwoven into a network that can ultimately mediate cell proliferation, apoptosis, and autophagy, thereby endowing tumor cells with more aggressive behaviors. Moreover, recent studies revealed that ERS could also impede the efficacy of anti-cancer treatment including immunotherapy by manipulating the TME. In this review, we discuss the relationship among bladder cancer, ERS, and TME; summarize the current research progress and challenges in overcoming therapeutic resistance; and explore the concept of targeting ERS to improve bladder cancer treatment outcomes.

Highlights

  • Bladder cancer is the fourth most common and eighth most lethal malignant tumor in men in the United States, accounting for an estimated number of 81,400 new cases and 17,980 deaths in the United States in 2020 (Siegel et al, 2020)

  • ER stress (ERS) and unfolded protein response (UPR) are widely involved in multiple cellular processes and cell fate determination, including cell proliferation, autophagy, apoptosis, and therapeutic resistance

  • A growing body of literature suggested that UPR plays a cytoprotective and pro-oncogenic role in cancer to enable cancer cells to cope with adverse microenvironmental stimuli, such as hypoxia, nutrient deficiency, and reactive oxygen species (ROS)

Read more

Summary

INTRODUCTION

Bladder cancer is the fourth most common and eighth most lethal malignant tumor in men in the United States, accounting for an estimated number of 81,400 new cases and 17,980 deaths in the United States in 2020 (Siegel et al, 2020). In China, a total of 80,500 new cases and 32,900 deaths were recorded in 2015 (Chen et al, 2016a)

ERS and TME in Bladder Cancer
ERS AND RELATED SIGNALING PATHWAYS
Association Between UPR Pathway and Classical Signaling Pathways
ERS and Bladder Cancer Cell Proliferation
ERS and Bladder Cancer Cell Apoptosis
ERS and Autophagy in Bladder Cancer
ERS and Bladder Cancer Cell Resistance
CROSSTALK BETWEEN ERS AND TME
Nutrient Deficiency
Reactive Oxygen Species
ERS as a Cancer Prognostic Marker
ERS and UPR as Therapeutic Targets
CONCLUSION
AUTHOR CONTRIBUTIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call